EN DE
Watch Aprilbio Co. Ltd. for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Aprilbio Co. Ltd. (397030) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Aprilbio Co. Ltd. stock ₩6,735, price ₩13,060, that is 48.4% below the price, quality 29 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

AC Aprilbio Co. Ltd. logo Thin data Nov 16, 2026

Aprilbio Co. Ltd.

397030 · KQ

Far too expensive (fair value 48% below the price), weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Mixed Growth (revenue 3y +121.5 %/yr in KRW) 
Revenue last quarter 67% below a year ago. 
Fair value ₩6,735 · Strongly overvalued 
Quality 29/100 
Falling price (downtrend) 
Negative free cash flow 
Trails peers (2/6) 
Narrow moat 5/100
Thin data 
Estimate
Watch Aprilbio Co. Ltd. for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₩73,300 ₩5,400 Fair Value ₩6,735 Jul 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

52‑month range ₩5,400 – ₩73,300 · fair‑value band ₩5,052 – ₩8,419 · the ₩13,060 price screens above the ₩6,735 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Aprilbio Co. in your weekly email

Every Wednesday you see whether Aprilbio Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AprilBio Co.,Ltd. develops long-acting type biobetter and antibody biologics. The company develops antibody drugs, double antibodies, long-acting antibody drugs, long-acting protein drugs, and ADC-applied antibodies.

Show moreShow less

It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases. The company was founded in 2013 and is headquartered in Chuncheon-si, South Korea.

Stock analysis

Aprilbio Co. Ltd. (397030) currently trades at ₩13,060, while our estimate is ₩6,735, 48% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ₩5,052 (bear) to ₩8,419 (bull), the price of ₩13,060 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Aprilbio Co. Ltd. reported revenue of 2.2B KRW in FY2025 versus 23.4B KRW in FY2021, a compound −44.8%/yr. Reported net income was −9.7B KRW in FY2025.

Key figures

Market cap 303B KRW (≈ $227M) Micro · EPS (TTM) ₩-385 · Return on equity −9.7% · Return on assets (EBIT) −3.3% (5-year average) · Operating margin −1,324% · Revenue (TTM) 725M KRW · Revenue growth (YoY) −66.6% · EPS growth (YoY) −66.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (medium confidence).

What moves the price

The share trades about 82% below its 52-week high and 22% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −48%, 397030 screens richer than that median.

Fair Value

Bear ₩5,052 Fair Value ₩6,735 Bull ₩8,419
Price ₩13,060 · Downside -48.4%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 10
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 81
Debt, balance sheet and risk of trouble
Investment 41
Does it invest with discipline instead of growing at any price?
Low Volatility 7
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 48
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 28/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−92.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+121.5%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
19.0% (2021) → −334.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

397030 screens overvalued: fair value 48% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Aprilbio Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −48.4% · Bottom 25%
Profitability
Return on assets −10.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) −66.6% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.15× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $923.34 $1,275.02 +38% vs 397030
Vertex Pharmaceuticals Incorporated VRTX $520.66 $587.62 +13% vs 397030
Samsung Biologics Co 207940 ₩1,375,000 ₩1,512,500 +10% vs 397030
argenx SE ARGX $942.04 $908.40 −4% vs 397030
CSL Limited CSL A$197.29 A$188.80 −4% vs 397030
BeOne Medicines AG 6160 HK$242.60 HK$152.92 −37% vs 397030
Moderna, Inc MRNA $199.33 $122.98 −38% vs 397030
Revolution Medicines, Inc RVMD $159.43 $83.12 −48% vs 397030
Celltrion, Inc 068270 ₩215,000 ₩74,574 −65% vs 397030
Royalty Pharma plc RPRX $67.72 $19.01 −72% vs 397030

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Aprilbio Co. Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Aprilbio Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/397030

Frequently asked questions

Is Aprilbio Co. Ltd. (397030) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is ₩6,735 versus a price of ₩13,060, about 48% lower (overvalued).
What is the fair value of 397030?
Our estimate for Aprilbio Co. Ltd. is ₩6,735 (as of Nov 16, 2026), built from audited fundamentals. The current price: ₩13,060.
What is the quality score of 397030?
Aprilbio Co. Ltd. has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aprilbio Co. Ltd. (397030)?
We do not set a price target; the yardstick is our estimate of ₩6,735 (as of Nov 16, 2026). Cautious scenario ₩5,052, optimistic scenario ₩8,419. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the Aprilbio Co. Ltd. stock forecast for 2026?
Our estimate puts fair value at ₩6,735, about 48% lower versus a price of ₩13,060 (overvalued). Cautious scenario ₩5,052, optimistic scenario ₩8,419. The calculation is refreshed regularly with new filings.
What is the revenue of Aprilbio Co. Ltd. (397030)?
Aprilbio Co. Ltd. reported trailing-twelve-month revenue of about 725M KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Aprilbio Co. Ltd. (397030)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aprilbio Co. Ltd. it is ₩6,735 per share (as of Nov 16, 2026), against a price of ₩13,060.
Is Aprilbio Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 397030 trades above its calculated fair value: price ₩13,060, fair value ₩6,735, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 397030?
No. The price is what the market pays today (₩13,060); the fair value is what the company's own numbers justify (₩6,735). For Aprilbio Co. Ltd. the two are ₩6,325 per share apart. That gap is exactly why we show both numbers side by side.
How much is Aprilbio Co. Ltd. worth?
The market values Aprilbio Co. Ltd. at about 303B KRW (market capitalisation, as of Nov 16, 2026). Per share that is ₩13,060; our models calculate a fair value of ₩6,735 per share.
What do the bullish and bearish scenarios say about 397030?
Our models span a range for Aprilbio Co. Ltd.: cautious scenario ₩5,052, base ₩6,735, optimistic ₩8,419 per share (as of Nov 16, 2026, price ₩13,060). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Aprilbio Co. Ltd. (397030)?
Balance-sheet figures for Aprilbio Co. Ltd. (as of Nov 16, 2026): return on equity −9.7%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is 397030 from its 52-week high?
Aprilbio Co. Ltd. trades at ₩13,060, about 82% below its 52-week high of ₩73,300 and 22% above the low of ₩10,700 (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of ₩6,735 is for.
Which stocks are comparable to Aprilbio Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aprilbio Co. Ltd. stock attractive at the current price?
The data as of Nov 16, 2026: price ₩13,060, calculated fair value ₩6,735 (−48%), Quality Score 29/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 11.0% above its aggregate fair value. Aprilbio Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aprilbio Co. Ltd. (397030)?
The closing price on Nov 19, 2026 was ₩13,060. Our estimate is ₩6,735, about 48% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aprilbio Co. Ltd. right now?
The price sits above even our optimistic bull case (₩8,419). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Aprilbio Co. Ltd.

How large is the market capitalisation of Aprilbio Co. Ltd. (397030)?
The market capitalisation of Aprilbio Co. Ltd. is 303B KRW (≈ $227M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Aprilbio Co. Ltd. (397030)?
Earnings per share at Aprilbio Co. Ltd. are ₩-385. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Aprilbio Co. Ltd. (397030)?
The return on equity (ROE) of Aprilbio Co. Ltd. is −9.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aprilbio Co. Ltd. (397030)?
On an EBIT basis the return on assets of Aprilbio Co. Ltd. is −3.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aprilbio Co. Ltd. (397030)?
The operating margin of Aprilbio Co. Ltd. is −1,324% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aprilbio Co. Ltd. (397030)?
Revenue at Aprilbio Co. Ltd. is down 66.6% versus a year earlier (3y avg +121%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Aprilbio Co. Ltd. (397030)?
Earnings per share at Aprilbio Co. Ltd. are down 66.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Aprilbio Co. Ltd. (397030) generate?
The free cash flow of Aprilbio Co. Ltd. is −3.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Aprilbio Co. Ltd. in the live analysis

One click puts Aprilbio Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.